Pila Pharma Starts Safety Part of Obesity Trial PP-CT04
Pila Pharma AB (publ) has enrolled the first subject in Part 1 (safety) of PP-CT04, a 12-week randomized, double-blind, placebo-controlled trial of XEN-D0501 in obesity.
Pila Pharma AB (publ) has enrolled the first subject in Part 1 (safety) of PP-CT04, a 12-week randomized, double-blind, placebo-controlled trial of XEN-D0501 in obesity.